Ilker Yalcin

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Comparison of physician and patient assessments of incontinence severity and improvement
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, IN, USA
    Int Urogynecol J Pelvic Floor Dysfunct 18:1291-5. 2007
  2. doi request reprint Reductions in stress urinary incontinence episodes: what is clinically important for women?
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Neurourol Urodyn 29:344-7. 2010
  3. ncbi request reprint The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, IN, USA
    Am J Obstet Gynecol 191:194-7. 2004
  4. ncbi request reprint Validation of a clinical algorithm to diagnose stress urinary incontinence for large studies
    Ilker Yalcin
    Lilly Research Laboratories and Methodist Hospital, Indiana University School of Medicine, Indianapolis, Indiana, USA
    J Urol 171:2321-5. 2004
  5. doi request reprint Patient reported outcomes tools in an observational study of female stress urinary incontinence
    Huub van de Vaart
    Department of Perinatology and Gynaecology, University Medical Centre, Utrecht, Netherlands
    Neurourol Urodyn 29:348-53. 2010
  6. ncbi request reprint Validation of two global impression questionnaires for incontinence
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Am J Obstet Gynecol 189:98-101. 2003
  7. ncbi request reprint Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Urology 67:1304-8. 2006
  8. ncbi request reprint A retrospective pooled analysis of duloxetine safety in 23,983 subjects
    James Gahimer
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 23:175-84. 2007
  9. ncbi request reprint Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response
    Richard C Bump
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Obstet Gynecol 102:76-83. 2003
  10. ncbi request reprint Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety
    Daniel J Hurley
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur J Obstet Gynecol Reprod Biol 125:120-8. 2006

Detail Information

Publications20

  1. ncbi request reprint Comparison of physician and patient assessments of incontinence severity and improvement
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, IN, USA
    Int Urogynecol J Pelvic Floor Dysfunct 18:1291-5. 2007
    ..46 and 0.44). In this study, the subjective (patient) and objective (clinician) assessments of SUI improvement with treatment appear to be more closely aligned than are the assessments of initial SUI severity...
  2. doi request reprint Reductions in stress urinary incontinence episodes: what is clinically important for women?
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Neurourol Urodyn 29:344-7. 2010
    ..To expand our understanding of the clinical importance to patients with stress urinary incontinence (SUI) of reductions in incontinence episode frequency (IEF) that fall short of a complete cure...
  3. ncbi request reprint The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, IN, USA
    Am J Obstet Gynecol 191:194-7. 2004
    ..The aim of this study was to examine the relationship between previous treatment experience and baseline urinary incontinence severity with placebo response...
  4. ncbi request reprint Validation of a clinical algorithm to diagnose stress urinary incontinence for large studies
    Ilker Yalcin
    Lilly Research Laboratories and Methodist Hospital, Indiana University School of Medicine, Indianapolis, Indiana, USA
    J Urol 171:2321-5. 2004
    ..Such an algorithm would have applicability to ensure that the majority of women entering large SUI clinical trials would have urodynamic SUI and/or the condition of SUI without performing urodynamic testing in all subjects...
  5. doi request reprint Patient reported outcomes tools in an observational study of female stress urinary incontinence
    Huub van de Vaart
    Department of Perinatology and Gynaecology, University Medical Centre, Utrecht, Netherlands
    Neurourol Urodyn 29:348-53. 2010
    ....
  6. ncbi request reprint Validation of two global impression questionnaires for incontinence
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Am J Obstet Gynecol 189:98-101. 2003
    ..The purpose of this study was to assess the construct validity of two global assessment questions, the Patient Global Impression of Severity and of Improvement, in female patients with stress urinary incontinence...
  7. ncbi request reprint Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence
    Ilker Yalcin
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Urology 67:1304-8. 2006
    ....
  8. ncbi request reprint A retrospective pooled analysis of duloxetine safety in 23,983 subjects
    James Gahimer
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 23:175-84. 2007
    ..The objective of this manuscript is to characterize the overall safety profile of duloxetine, regardless of indication, based on data from the duloxetine exposures integrated safety database...
  9. ncbi request reprint Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response
    Richard C Bump
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Obstet Gynecol 102:76-83. 2003
    ..To investigate the relationship between the symptom of mixed urinary incontinence and incontinence severity, urodynamic findings, and treatment response...
  10. ncbi request reprint Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety
    Daniel J Hurley
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur J Obstet Gynecol Reprod Biol 125:120-8. 2006
    ..The objective was to characterize the safety of duloxetine for treatment of stress urinary incontinence (SUI) in women, using an integrated database generated from four published placebo-controlled clinical trials...
  11. ncbi request reprint Duloxetine treatment of stress urinary incontinence in women: effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus, and depression on efficacy
    Lars Viktrup
    Duloxetine Urinary Incontinence Study Group, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur J Obstet Gynecol Reprod Biol 133:105-13. 2007
    ..Duloxetine has been shown to be effective in women with stress urinary incontinence (SUI)...
  12. ncbi request reprint Safety and adverse event profile of duloxetine
    Joachim F Wernicke
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Expert Opin Drug Saf 4:987-93. 2005
    ..The purpose of this review is to provide an overview of some of the most important information related to safety and tolerability of duloxetine...
  13. ncbi request reprint Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence
    Alfred E Bent
    Greater Baltimore Medical Center, Baltimore, Maryland, USA
    Obstet Gynecol 106:767-73. 2005
    ..To evaluate the reproducibility, construct validity, and preferences for the 2-item Stress/Urge Incontinence Questionnaire...
  14. ncbi request reprint Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence
    David Castro-Diaz
    Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
    Int Urogynecol J Pelvic Floor Dysfunct 18:919-29. 2007
    ..Starting duloxetine at 20 mg BID for 2 weeks before increasing to 40 mg BID significantly improved tolerability but did not impact duloxetine efficacy after all the subjects had been on 40 mg BID for at least 2 weeks...
  15. ncbi request reprint A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence
    Gamal M Ghoniem
    Cleveland Clinic Florida, Weston, Florida, USA
    J Urol 173:1647-53. 2005
    ..In addition, we compared the effectiveness of combined treatment with single treatments, single treatments with each other and single treatments with no treatment...
  16. ncbi request reprint Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence
    Philip van Kerrebroeck
    Department of Urology, University Hospital Maastrecht, Netherlands
    BJOG 111:249-57. 2004
    ..To assess the efficacy and safety of duloxetine in women with stress urinary incontinence...
  17. ncbi request reprint Duloxetine compared with placebo for treating women with symptoms of overactive bladder
    William D Steers
    University of Virginia, Charlottesville, Virginia, USA
    BJU Int 100:337-45. 2007
    ..To evaluate duloxetine (a serotonin-noradrenaline reuptake inhibitor) in women with symptoms of overactive bladder (OAB), as it has been shown to increase the bladder capacity in an animal model...
  18. ncbi request reprint Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence
    Alfred E Bent
    Greater Baltimore Medical Center, Baltimore, Maryland, USA
    Neurourol Urodyn 27:212-21. 2008
    ..Evaluate duloxetine in the treatment of women with mixed urinary incontinence (MUI)...
  19. ncbi request reprint Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence
    Roger R Dmochowski
    Department of Urologic Surgery, Vanderbilt University, Nashville, Tennessee, USA
    J Urol 170:1259-63. 2003
    ..In this first phase 3 study we assessed the efficacy and safety of duloxetine in women with stress urinary incontinence (SUI)...
  20. ncbi request reprint Duloxetine versus placebo in the treatment of stress urinary incontinence
    Peggy A Norton
    Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, USA
    Am J Obstet Gynecol 187:40-8. 2002
    ..The purpose of this study was to assess the efficacy and safety of duloxetine, a selective inhibitor of serotonin and norepinephrine reuptake, in the treatment of stress urinary incontinence...